Congress Asset Management Co. Buys 1,454 Shares of Eli Lilly and Company $LLY

Congress Asset Management Co. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 124,514 shares of the company’s stock after acquiring an additional 1,454 shares during the period. Eli Lilly and Company accounts for about 0.9% of Congress Asset Management Co.’s investment portfolio, making the stock its 23rd largest position. Congress Asset Management Co.’s holdings in Eli Lilly and Company were worth $144,073,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. RVW Wealth LLC boosted its stake in Eli Lilly and Company by 93.8% during the 3rd quarter. RVW Wealth LLC now owns 4,187 shares of the company’s stock valued at $4,845,000 after purchasing an additional 2,027 shares during the period. Colton Groome Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the third quarter worth $204,000. Financial Symmetry Inc increased its holdings in Eli Lilly and Company by 34.2% in the 3rd quarter. Financial Symmetry Inc now owns 459 shares of the company’s stock valued at $531,000 after buying an additional 117 shares during the period. Byrne Asset Management LLC increased its holdings in Eli Lilly and Company by 11.4% in the 3rd quarter. Byrne Asset Management LLC now owns 576 shares of the company’s stock valued at $662,000 after buying an additional 59 shares during the period. Finally, Rosenberg Matthew Hamilton raised its stake in shares of Eli Lilly and Company by 2.1% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 764 shares of the company’s stock valued at $884,000 after buying an additional 16 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma patients without a 17p deletion. The decision, supported by Phase 3 data, could expand the drug’s addressable market and strengthen Lilly’s oncology growth. FDA expands Eli Lilly’s blood cancer drug label
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The status may provide development incentives and potential market exclusivity, reinforcing Lilly’s strategy to diversify beyond GLP-1 medicines. Lilly expands oncology footprint
• Positive Sentiment: New analysis presented at the European Association for the Study of Diabetes meeting showed Lilly’s oral GLP-1 candidate Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. If confirmed in later-stage studies and commercialized successfully, the pill could extend Lilly’s metabolic-health leadership. Foundayo analysis versus oral semaglutide
• Positive Sentiment: Lilly expanded its collaboration with Gate Bioscience in a potential agreement worth more than $870 million, while also making its insitro-developed machine-learning models available through Lilly TuneLab. These deals could improve future drug discovery and add longer-term pipeline value. Lilly expands Gate Bioscience collaboration
• Neutral Sentiment: Early-stage updates for Lilly’s elt­re­kibart antibody and a new basal-insulin candidate indicate continued pipeline progress, but Phase 1 results do not yet establish commercial viability. Lilly also plans 21 dermatology presentations, potentially providing additional catalysts later this month.
• Negative Sentiment: Analysts and commentators cautioned that LLY’s valuation—roughly 38 times earnings, well above the broader market—already reflects very high growth expectations. Any slowdown in Zepbound or Mounjaro demand, pricing pressure, trial setbacks or regulatory delays could leave limited room for error. Eli Lilly valuation risk

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Citigroup increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Guggenheim raised their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Finally, Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,311.96.

Eli Lilly and Company Price Performance

LLY stock traded up $14.49 during trading on Tuesday, hitting $1,157.61. 2,130,131 shares of the stock traded hands, compared to its average volume of 2,977,802. The stock has a market cap of $1.09 trillion, a price-to-earnings ratio of 38.85, a P/E/G ratio of 1.40 and a beta of 0.46. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a 50 day simple moving average of $1,175.28 and a 200 day simple moving average of $1,090.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts expect that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.